Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799804 | 0.99 | SLC6A3 (0.62) | SLC6A3PDE5APTGS1TBXAS1PTGS2 | |
| SCHEMBL17799892 | 0.95 | SLC6A3 (0.55) | SLC6A3ACP1 | |
| SCHEMBL17799794 | 0.91 | SLC6A3 (0.64) | SLC6A3PDE5APTGS1TBXAS1PTGS2 | |
| SCHEMBL17799810 | 0.89 | SLC6A3 (0.63) | SLC6A3PDE5AACP1 | |
| SCHEMBL17799961 | 0.87 | SLC6A3 (0.65) | SLC6A3PDE5AACP1 | |
| SCHEMBL17799998 | 0.85 | SLC6A3 (0.61) | SLC6A3ACP1 | |
| SCHEMBL17799799 | 0.85 | SLC6A3 (0.57) | SLC6A3PDE5APTGS1TBXAS1PTGS2 | |
| SCHEMBL17799866 | 0.85 | SLC6A3 (0.63) | SLC6A3ACP1 | |
| SCHEMBL17800077 | 0.85 | SLC6A3 (0.46) | SLC6A3PDE5AACP1KDM4EMAPK1 | |
| SCHEMBL17799828 | 0.85 | PDE5A (0.46) | SLC6A3PDE5AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| WO-2016090296-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A3 3/4885PDE5A 836/4885PTGS1 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.